@article{3110880,
    title = "Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine",
    author = "Miltiades, P. and Lamprianidou, E. and Vassilakopoulos, T.P. and Papageorgiou, S.G. and Galanopoulos, A.G. and Vakalopoulou, S. and Garypidou, V. and Papaioannou, M. and Hadjiharissi, E. and Pappa, V. and Papadaki, H.A. and Spanoudakis, E. and Tsatalas, K. and Kotsianidis, I.",
    journal = "Blood cancer journal",
    year = "2014",
    volume = "4",
    number = "2",
    publisher = "Nature Publishing Group",
    doi = "10.1038/bcj.2014.9",
    keywords = "antianemic agent;  azacitidine;  granulocyte colony stimulating factor;  interleukin 2 receptor alpha, aged;  antigen expression;  CD34+ cell;  cell type;  chronic myelomonocytic leukemia;  controlled study;  disease course;  down regulation;  event free survival;  female;  flow cytometry;  follow up;  human;  letter;  major clinical study;  male;  myelodysplastic syndrome;  outcome assessment;  overall survival;  relapse;  survival;  treatment duration;  treatment response"
}